Accessibility Menu
ImpediMed logo

ImpediMed(OTC) IPDQF

Current Price$0.01
Market Cap$20.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)-99%
5 Year-94%
1 Year-86%
1 Month-7%
ImpediMed last closing stock price
MetricPriceDate
Last closeUSD 0.012026-07-10
ImpediMed stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+10.66%USD 0.002026-06-29
1 month-7.22%USD 0.012026-06-01
3 month-32.1%USD 0.012026-04-10
Year to date-75%USD 0.022025-12-23
1 year-85.86%USD 0.042025-07-07
3 year-95%USD 0.112023-07-10
5 year-93.6%USD 0.092021-07-07
Since inception-98.72%USD 0.432008-11-13

ImpediMed Financials at a Glance

Market Cap

$20.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$25.77M

Net Income (TTM)

-A$45.59M

EPS (TTM)

-$0.01

P/E Ratio

-0.71

Dividend

$0.00

Beta (Volatility)

0.32 (Low)

Price

$0.01

Volume

250,000

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.00 - $0.05

Estimated Earnings Date

Aug 27, 2026

IPDQF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ImpediMed

ImpediMed Limited is a medical technology firm specializing in software solutions and bioimpedance spectroscopy (BIS) equipment. The company focuses on the creation, production, and global distribution of advanced medical devices, primarily serving markets in Australia and North America.

Products and Services
  • SOZO: A non-intrusive BIS device for evaluating lymphedema and tracking fluid levels
  • SFB7: A single-channel BIS instrument for assessing body composition in healthy individuals
  • ImpediVET: A BIS device tailored for veterinary applications to measure fluid status in animals
Growth Outlook
  • Recent quarterly revenue increased to AUD 7.5 million, reflecting growing market demand
  • Expansion into North American markets is expected to drive future revenue growth
  • Investment in R&D aims to enhance product offerings and improve market competitiveness
Financial Highlights
  • Trailing twelve-month revenue of AUD 25.5 million indicates a solid revenue base
  • Current ratio of 3.74 suggests strong liquidity and ability to meet short-term obligations
  • Cash and cash equivalents of AUD 18.8 million provide a buffer for operational needs
ImpediMed Limited is positioned in the healthcare sector, focusing on innovative medical devices that address critical health issues. The company's flagship products, such as SOZO, are designed to improve patient outcomes through non-invasive monitoring techniques. With a strong emphasis on research and development, ImpediMed aims to expand its product line and enhance its market presence, particularly in North America. Recent financial performance shows promising revenue growth, supported by a robust liquidity position, which may attract potential investors looking for opportunities in the medical technology space.
AI Generated • Jul 8, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

77

CEO

Parmjot Bains, PhD

Website

www.impedimed.com

Headquarters

Pinkenba, QLD 4008, AU

IPDQF Financials

Key Financial Metrics (TTM)

Gross Margin

-5.85%

Operating Margin

-156.48%

Net Income Margin

-171.25%

Return on Equity

-165.13%

Return on Capital

-69.26%

Return on Assets

-63.53%

Earnings Yield

-1.41%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$20.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.66B

Volume

250.00K

Avg. Volume

18.84K

Financials (TTM)

Gross Profit

A$9.31M

Operating Income

-A$23.31M

EBITDA

-A$35.89M

Operating Cash Flow

-A$35.16M

Capital Expenditure

A$6.57M

Free Cash Flow

-A$28.59M

Cash & ST Invst.

A$18.84M

Total Debt

A$21.93M

ImpediMed Performance Analysis

ImpediMed annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 7,663,369N/A
20232023-06-30AUD 7,631,160-0.4%
20242024-06-30AUD 6,762,815-11.4%
20252025-06-30AUD 8,240,45721.8%
ImpediMed sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3015.7%
Q22024-12-318.5%
Q42025-06-3011.8%
Q22025-12-3111.9%
ImpediMed annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.01N/A
20232023-06-30AUD -0.01-10.5%
20242024-06-30AUD -0.01-16.9%
20252025-06-30AUD -0.0117.2%
ImpediMed sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30N/A
Q22024-12-3130.6%
Q42025-06-30-76.5%
Q22025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$7.51M

+57.0%

Gross Profit

-A$6.51M

+16.8%

Gross Margin

-86.70%

N/A

Market Cap

$20.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$261.61K

N/A

Employees

77

N/A

Net Income

-A$12.28M

-26.3%

EBITDA

-A$7.50M

-41.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$18.84M

-49.0%

Total Debt

A$21.93M

+1622.3%

Accounts Receivable

A$3.75M

+86.8%

Inventory

A$2.27M

+152.1%

Long Term Debt

A$21.62M

+2145.3%

Short Term Debt

A$302.88K

-2.3%

Return on Assets

-63.53%

N/A

Return on Invested Capital

-70.68%

N/A

Free Cash Flow

A$0.00

+100.0%

Operating Cash Flow

-A$9.50M

-40.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PETVPetVivo Holdings, Inc.
$0.69-10.00%
PYNKFPerimeter Medical Imaging AI, Inc.
$0.23+4.55%
POSCPositron Corporation
$1.66-1.37%
FNCHFinch Therapeutics Group, Inc.
$10.00-0.99%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.28-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
INTCIntel
$102.62-0.03%

Questions About IPDQF

What is the current price of ImpediMed?

ImpediMed is trading at $0.01 per share.

What is the 52-week range for ImpediMed?

Over the past 52 weeks, ImpediMed has traded between $0.00 and $0.05.

How much debt does ImpediMed have?

As of the most recent reporting period, ImpediMed reported total debt of A$9.50M.

How much cash does ImpediMed have on hand?

ImpediMed reported A$14.54M in cash and cash equivalents in its most recent financial results.

What is ImpediMed’s dividend yield?

ImpediMed does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services